Dr Hope Rugo: Will Herceptin Become a Non-Preferred Drug?

Hope Rugo, MD, director of the breast oncology clinical trials program at the University of California at San Francisco, discusses how payers might address Herceptin after the advent of biosimilar trastuzumab. 
February 22, 2018


Humana recently reclassified Herceptin from a preferred drug to a non-preferred drug in some Florida markets. Have you heard of this happening elsewhere?

I haven’t heard of a reclassification to a non-preferred drug. I think that they’re doing that ahead of time in preparation for the biosimilar availability in the next year. I’m guessing that that will happen wholesale, that every regulatory group and mass insurer will change to say trastuzumab is what is preferred, and the type of trastuzumab doesn’t matter.



Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2020 Intellisphere, LLC. All Rights Reserved.